With the growing globalization of clinical trials, greater complexity of study designs and the move from site-centric to patient-centric studies, issues of data integrity loom larger than ever. And those issues continue to evolve, the FDA's David Burrow said Tuesday as he opened the first FDA/MHRA joint workshop on good clinical practices.